Imugene Limited's (ASX:IMU) (OTCMKTS:IUGNF) Leslie Chong discusses with Proactive's Andrew Scott the news the phase one clinical trial of its checkpoint immunotherapy candidate, PD1-Vaxx, will proceed to the second dose. She says the cohort review committee agreed the therapy to be safe with no dose-limitiing toxicities and no serious adverse reactions for the first three patients dosed.
Imugene's Leslie Chong details dose escalation for its phase I clinical trial of PD1-Vaxx
Quick facts: Imugene Ltd
Price: 0.105 AUD
Market Cap: $499.6 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Imugene Ltd named herein, including the promotion by the Company of Imugene Ltd in any Content on the Site, the Company receives from said...FOR OUR FULL DISCLAIMER CLICK HERE